These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 9850482)

  • 1. The effects of treatment on the direct costs of diabetes.
    Herman WH; Eastman RC
    Diabetes Care; 1998 Dec; 21 Suppl 3():C19-24. PubMed ID: 9850482
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk.
    Cleveringa FG; Welsing PM; van den Donk M; Gorter KJ; Niessen LW; Rutten GE; Redekop WK
    Diabetes Care; 2010 Feb; 33(2):258-63. PubMed ID: 19933991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia.
    Eastman RC; Javitt JC; Herman WH; Dasbach EJ; Copley-Merriman C; Maier W; Dong F; Manninen D; Zbrozek AS; Kotsanos J; Garfield SA; Harris M
    Diabetes Care; 1997 May; 20(5):735-44. PubMed ID: 9135935
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The cost-effectiveness of intensive therapy for diabetes mellitus.
    Herman WH; Dasbach EJ; Songer TJ; Eastman RC
    Endocrinol Metab Clin North Am; 1997 Sep; 26(3):679-95. PubMed ID: 9314022
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Policy evaluation in diabetes prevention and treatment using a population-based macro simulation model: the MICADO model.
    van der Heijden AA; Feenstra TL; Hoogenveen RT; Niessen LW; de Bruijne MC; Dekker JM; Baan CA; Nijpels G
    Diabet Med; 2015 Dec; 32(12):1580-7. PubMed ID: 26010494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost of managing complications resulting from type 2 diabetes mellitus in Canada.
    O'Brien JA; Patrick AR; Caro JJ
    BMC Health Serv Res; 2003 Mar; 3(1):7. PubMed ID: 12659641
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lifetime benefits and costs of intensive therapy as practiced in the diabetes control and complications trial. The Diabetes Control and Complications Trial Research Group.
    JAMA; 1996 Nov; 276(17):1409-15. PubMed ID: 8892716
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The impact of losartan on the lifetime incidence of end-stage renal disease and costs in patients with type 2 diabetes and nephropathy.
    Carides GW; Shahinfar S; Dasbach EJ; Keane WF; Gerth WC; Alexander CM; Herman WH; Brenner BM;
    Pharmacoeconomics; 2006; 24(6):549-58. PubMed ID: 16761903
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Economic costs of diabetes mellitus: critical review and cost-benefit evaluation of proposed strategies for its reduction].
    Rubio JA; Alvarez J
    Aten Primaria; 1998 Sep; 22(4):239-55. PubMed ID: 9803577
    [No Abstract]   [Full Text] [Related]  

  • 10. Assessing the impact of complications on the costs of Type II diabetes.
    Williams R; Van Gaal L; Lucioni C;
    Diabetologia; 2002 Jul; 45(7):S13-7. PubMed ID: 12136406
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of losartan on the lifetime incidence of ESRD and costs in Mexico.
    Arredondo A; Burke TA; Carides GW; Lemus E; Querol J
    Rev Invest Clin; 2005; 57(3):399-405. PubMed ID: 16187699
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How patients with diabetes perceive their risk for major complications.
    Meltzer D; Egleston B
    Eff Clin Pract; 2000; 3(1):7-15. PubMed ID: 10788040
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The 30-year cost-effectiveness of alternative strategies to achieve excellent glycemic control in type 1 diabetes: An economic simulation informed by the results of the diabetes control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC).
    Herman WH; Braffett BH; Kuo S; Lee JM; Brandle M; Jacobson AM; Prosser LA; Lachin JM
    J Diabetes Complications; 2018 Oct; 32(10):934-939. PubMed ID: 30064713
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The costs of treating long-term diabetic complications in a developing country: a study from India.
    Kumpatla S; Kothandan H; Tharkar S; Viswanathan V
    J Assoc Physicians India; 2013 Feb; 61(2):102-9. PubMed ID: 24471248
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The impact of patient preferences on the cost-effectiveness of intensive glucose control in older patients with new-onset diabetes.
    Huang ES; Shook M; Jin L; Chin MH; Meltzer DO
    Diabetes Care; 2006 Feb; 29(2):259-64. PubMed ID: 16443870
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensive glucose control versus conventional glucose control for type 1 diabetes mellitus.
    Fullerton B; Jeitler K; Seitz M; Horvath K; Berghold A; Siebenhofer A
    Cochrane Database Syst Rev; 2014 Feb; 2014(2):CD009122. PubMed ID: 24526393
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes.
    CDC Diabetes Cost-effectiveness Group
    JAMA; 2002 May; 287(19):2542-51. PubMed ID: 12020335
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An economic analysis of captopril in the treatment of diabetic nephropathy. The Collaborative Study Group.
    Rodby RA; Firth LM; Lewis EJ
    Diabetes Care; 1996 Oct; 19(10):1051-61. PubMed ID: 8886549
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The economics of screening and treatment in type 2 diabetes mellitus.
    Raikou M; McGuire A
    Pharmacoeconomics; 2003; 21(8):543-64. PubMed ID: 12751913
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.